Stanford Cancer Institute Breakthroughs in Cancer: David Hong, MD

"Targeting RAS: The Past, Present, and the Future," presented by David Hong, MD.
David Hong has been a key driver in establishing one of the most innovative and influential cancer-targeted phase I clinical trial units in the world at the University of Texas MD Anderson Cancer Center. He is a world leader in conducting early-phase clinical trials of kinase inhibitors and RAS inhibitors in cancer, many of which have led to FDA approval and changes in the standard of care. #kras
Breakthroughs in Cancer seminar series is one of the highest-profile seminar series for translational and clinical scientists in oncology. The series brings national leaders in cancer research to Stanford’s campus and highlights innovations across the spectrum of basic, translational, clinical, and population science. The series will be held in person on the second Tuesday of each month at Munzer Auditorium.
#oncology #cancerresearch #sciencemedicine
Learn more about our Breakthroughs in Cancer seminar series: med.stanford.edu/cancer/train...
Learn more about the Stanford Cancer Institute:
med.stanford.edu/cancer
Follow the Stanford Cancer Institute LinkedIn: / stanford-cancer
Twitter: / scidirector
Subscribe to the Stanford Cancer Institute: / @stanfordcancerinstitute